CN101257918B - 来自白介素-6家族的细胞因子在用于与干扰素-α组合施用的组合物的制备中的用途 - Google Patents

来自白介素-6家族的细胞因子在用于与干扰素-α组合施用的组合物的制备中的用途 Download PDF

Info

Publication number
CN101257918B
CN101257918B CN2006800299002A CN200680029900A CN101257918B CN 101257918 B CN101257918 B CN 101257918B CN 2006800299002 A CN2006800299002 A CN 2006800299002A CN 200680029900 A CN200680029900 A CN 200680029900A CN 101257918 B CN101257918 B CN 101257918B
Authority
CN
China
Prior art keywords
ifn
cytokine
family
combination
pegylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800299002A
Other languages
English (en)
Chinese (zh)
Other versions
CN101257918A (zh
Inventor
R·阿尔达贝阿勒吉
E·拉雷亚勒奥茨
M·P·西弗拉穆里洛
J·普里托瓦尔图纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of CN101257918A publication Critical patent/CN101257918A/zh
Application granted granted Critical
Publication of CN101257918B publication Critical patent/CN101257918B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
CN2006800299002A 2005-06-16 2006-06-16 来自白介素-6家族的细胞因子在用于与干扰素-α组合施用的组合物的制备中的用途 Expired - Fee Related CN101257918B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200501468 2005-06-16
ES200501468A ES2302402B1 (es) 2005-06-16 2005-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
PCT/ES2006/000353 WO2006134195A2 (es) 2005-06-16 2006-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa

Publications (2)

Publication Number Publication Date
CN101257918A CN101257918A (zh) 2008-09-03
CN101257918B true CN101257918B (zh) 2011-09-21

Family

ID=37532659

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800299002A Expired - Fee Related CN101257918B (zh) 2005-06-16 2006-06-16 来自白介素-6家族的细胞因子在用于与干扰素-α组合施用的组合物的制备中的用途

Country Status (11)

Country Link
US (2) US7829077B2 (https=)
EP (1) EP1905447A4 (https=)
JP (1) JP5154412B2 (https=)
CN (1) CN101257918B (https=)
AU (1) AU2006258966B8 (https=)
BR (1) BRPI0611988A2 (https=)
CA (1) CA2612282C (https=)
ES (1) ES2302402B1 (https=)
MX (1) MX2007016060A (https=)
RU (1) RU2413529C2 (https=)
WO (1) WO2006134195A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009762A1 (en) * 2008-07-23 2010-01-28 United Technologies Ut Ag Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection
JP2010059081A (ja) * 2008-09-02 2010-03-18 Okayama Univ オンコスタチンｍを含有する抗ｈｃｖ剤およびその利用
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
US20120308517A1 (en) * 2010-02-09 2012-12-06 Digna Biotech, S.L. Compositions for the treatment of infectious and tumoural diseases
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2018178215A1 (en) 2017-03-31 2018-10-04 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (nmsc)
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN113197910B (zh) * 2021-05-14 2022-09-23 苏州大学 一种基于阿司匹林及其代谢产物提高干扰素抗病毒活性的抗病毒药盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1001801B1 (fr) * 1997-08-04 2002-01-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant au moins un arn double brin en association avec au moins un interferon pour le traitement de l'hepatite virale

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284237B1 (en) 1986-07-08 2001-09-04 Steven C. Clark Methods of treatment using IL-6
IE67035B1 (en) * 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
US6348191B1 (en) 1986-07-08 2002-02-19 Genetics Institute, Inc. Production and use of IL-6
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
PT858343E (pt) * 1995-11-02 2004-07-30 Schering Corp Terapia por infusao continua de uma dose baixa de citoquina
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB9609932D0 (en) 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP2298900A1 (en) * 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
ES2200646B1 (es) * 2001-09-21 2005-05-01 Fundacion Para La Investigacion Medica Aplicada Uso de la cardiotrofina en enfermedades hepaticas.
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
RU2222345C2 (ru) * 2002-01-21 2004-01-27 Волчек Игорь Анатольевич Фармацевтическая композиция цитокинового и иммуномодулирующего действия
US20050027110A1 (en) * 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1001801B1 (fr) * 1997-08-04 2002-01-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant au moins un arn double brin en association avec au moins un interferon pour le traitement de l'hepatite virale

Also Published As

Publication number Publication date
JP2008546672A (ja) 2008-12-25
JP5154412B2 (ja) 2013-02-27
AU2006258966A1 (en) 2006-12-21
CN101257918A (zh) 2008-09-03
ES2302402A1 (es) 2008-07-01
AU2006258966B2 (en) 2011-11-17
CA2612282A1 (en) 2006-12-21
EP1905447A2 (en) 2008-04-02
ES2302402B1 (es) 2009-05-08
RU2008100307A (ru) 2009-07-27
CA2612282C (en) 2014-03-25
US7829077B2 (en) 2010-11-09
WO2006134195A8 (es) 2008-01-31
RU2413529C2 (ru) 2011-03-10
WO2006134195A2 (es) 2006-12-21
AU2006258966B8 (en) 2011-12-08
WO2006134195A3 (es) 2007-04-19
BRPI0611988A2 (pt) 2010-10-13
US20090130055A1 (en) 2009-05-21
US20110027224A1 (en) 2011-02-03
MX2007016060A (es) 2008-03-10
EP1905447A4 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
US20110027224A1 (en) Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha
De Maeyer et al. Type I interferons
JP4001379B2 (ja) ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用
Zhu et al. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication
Sutter et al. Interferon α subtypes in HIV infection
Choi et al. Stimulation of DDX3 expression by ginsenoside Rg3 through the Akt/p53 pathway activates the innate immune response via TBK1/IKKε/IRF3 signalling
Li et al. Administration of recombinant IFN1 protects zebrafish (Danio rerio) from ISKNV infection
Zayed et al. Association of toll-like receptor 3 and toll-like receptor 9 single nucleotide polymorphisms with hepatitis C virus infection and hepatic fibrosis in egyptian patients
US7666995B2 (en) Interferons, uses and compositions related thereto
Martínez-Espinoza et al. Current landscape of IFN-λ: induction, inhibition, and potential clinical applications to treat respiratory viral infections
Tang et al. IFN‐λ: Unleashing Its Potential in Disease Therapies From Acute Inflammation Regulation to Cancer Immunotherapy
Gruber et al. Differential signaling of cmvIL‐10 through common variants of the IL‐10 receptor 1
Fan et al. Molecular characterization of the type I IFN receptor in two woodchuck species and detection of its expression in liver samples from woodchucks infected with woodchuck hepatitis virus (WHV)
KR101928564B1 (ko) 인터페론 및 dna 메틸화 억제제를 유효성분으로 포함하는, b형 간염 바이러스 감염증 예방 및 치료용 약학적 조성물
Ishida et al. Differential effects of a novel IFN-ζ/limitin and IFN-α on signals for Daxx induction and Crk phosphorylation that couple with growth control of megakaryocytes
Oritani et al. Interferon-ζ/limitin: novel type I interferon that displays a narrow range of biological activity
WO2005016226A2 (en) Pharmaceutical compositions comprising ccr5 antagonists
CN116688095A (zh) 受体酪氨酸激酶fgfr1的抗疱疹病毒作用及其应用
CN114404572A (zh) 一种抗SARS-CoV2病毒感染导致的细胞因子风暴的药物
Larrea et al. IFN-α 5 Mediates Stronger Tyk2-Stat-Dependent Activation and Higher Expression of 2′, 5′-Oligoadenylate Synthetase Than IFN-α 2 in Liver Cells
US20080069800A1 (en) System for High Production of Natural and Personalized Interferons
Chen et al. IFNA2 p. Ala120Thr impairs the inhibitory activity of Interferon-α2 against the hepatitis B virus through altering its binding to the receptor
Ningrum Human interferon Alpha2a as anti Hepatitis B and C
Yu et al. Cyprinid fish ubiquitin-specific protease 18 (USP18) downregulates the basal and induced interferon expression
Aslam et al. Interferon α2–Thymosin α1 Fusion Protein (IFNα2–Tα1): A Genetically Engineered Fusion Protein with Enhanced Anticancer and Antiviral Effect. Materials 2021, 14, 3318

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110921

Termination date: 20150616

EXPY Termination of patent right or utility model